120 related articles for article (PubMed ID: 37957096)
1. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
Zhao X; Gu C; Wang Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
[No Abstract] [Full Text] [Related]
2. PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells.
Zhao X; Gu C; Wang Y
Int Immunopharmacol; 2020 Nov; 88():106923. PubMed ID: 32889238
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
[No Abstract] [Full Text] [Related]
4. Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.
Jones JE; Slack JL; Fang P; Zhang X; Subramanian V; Causey CP; Coonrod SA; Guo M; Thompson PR
ACS Chem Biol; 2012 Jan; 7(1):160-5. PubMed ID: 22004374
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to 'Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways'. [Int. Immunopharmacol. 75 (2019) 105739].
Li Y; Zeng Y; Meng T; Gao X; Huang B; He D; Ran X; Du J; Zhang Y; Fu S; Hu G
Int Immunopharmacol; 2020 Jul; 84():105962. PubMed ID: 31948857
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
[No Abstract] [Full Text] [Related]
8. Retraction notice to "Salidroside protects ATDC5 cells against lipopolysaccharide-induced injury through up-regulation of microRNA-145 in osteoarthritis" [Int. Immunopharmacol. 67 (2019) 441-448].
Liu M; Zhang J; Liu W; Wang W
Int Immunopharmacol; 2021 Jun; 95():107711. PubMed ID: 33933373
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
Guo R; Li Y; Han M; Liu J; Sun Y
Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
[No Abstract] [Full Text] [Related]
10. Corrigendum to "6-Gingerol protects against cerebral ischemia/reperfusion injury by inhibiting NLRP3 inflammasome and apoptosis via TRPV1/FAF1 complex dissociation-mediated autophagy" [Int. Immunopharmacol. 100 (2021) 108146].
Luo J; Chen J; Yang C; Tan J; Zhao J; Jiang N; Zhao Y
Int Immunopharmacol; 2023 Aug; 121():110411. PubMed ID: 37308372
[No Abstract] [Full Text] [Related]
11. PIM1 inhibitor SMI-4a attenuated lipopolysaccharide-induced acute lung injury through suppressing macrophage inflammatory responses via modulating p65 phosphorylation.
Wang J; Cao Y; Liu Y; Zhang X; Ji F; Li J; Zou Y
Int Immunopharmacol; 2019 Aug; 73():568-574. PubMed ID: 31203114
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis" [Int. Immunopharmacol. 109 (2022) 108770].
Bao C; Liu C; Liu Q; Hua L; Hu J; Li Z; Xu S
Int Immunopharmacol; 2023 Feb; 115():109482. PubMed ID: 36610897
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Methylallyl sulfone attenuates inflammation, oxidative stress and lung injury induced by cigarette smoke extract in mice and RAW264.7 cells" Int Immunopharmacol, volume 59, 2018, 369-374.
Li A; Liu Y; Zhu X; Sun X; Feng X; Li D; Zhang J; Zhu M; Zhao Z
Int Immunopharmacol; 2019 Jul; 72():522. PubMed ID: 30922802
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Protective effect of tormentic acid from Potentilla chinensis against lipopolysaccharide/D-galactosamine induced fulminant hepatic failure in mice" [Int. Immunopharmacol. 19 (2014) 365-372].
Lin X; Zhang S; Huang R; Tan S; Liang S; Wu X; Zhuo L; Huang Q
Int Immunopharmacol; 2021 Jan; 90():107244. PubMed ID: 33309532
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway" [Int. Immunopharmacol. 75 (2019) 105759].
Wen S; Wei Y; Zhang X; Bai F; Tan S; Nie J; Wei J; Lin X
Int Immunopharmacol; 2021 Mar; 92():107344. PubMed ID: 33418247
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Tissue factor promotes airway pathological features through epithelial-mesenchymal transition of bronchial epithelial cells in mice with house dust mite-induced asthma" [Int. Immunopharmacol. 97 (2021) 107690].
Zhao J; Jiang T; Li P; Dai L; Shi G; Jing X; Gao S; Jia L; Wu S; Wang Y; Peng Y; Cheng Z
Int Immunopharmacol; 2022 Jul; 108():108886. PubMed ID: 35650002
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Modulating endoplasmic reticulum stress attenuates mast cell degranulation" [Int. Immunopharmacol. 126 (2024) 111336].
Fan J; Ma L; Xie B; Qiu S; Song S; Tang Z; Wu Y; Huangfu H; Feng Y; Luo X; Yang P
Int Immunopharmacol; 2024 Jun; ():112497. PubMed ID: 38902129
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259].
Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
Int Immunopharmacol; 2024 Jan; 126():111189. PubMed ID: 38012900
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS)" [Int. Immunopharmacol. 91 (2021) 107264].
Kumar A; Sawhney G; Kumar Nagar R; Chauhan N; Gupta N; Kaul A; Ahmed Z; Sangwan PL; Satheesh Kumar P; Yadav G
Int Immunopharmacol; 2022 Oct; 111():109003. PubMed ID: 35778365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
